Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Paxmedica Inc (PXMD)

Paxmedica Inc (PXMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently announced that it has completed its three registration/validation batches of PAX-101,...

PXMD : 0.2401 (-1.52%)
PaxMedica (NASDAQ: PXMD) Featured in Latest Bell2Bell Podcast Release

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, was featured in the latest episode of The Bell2Bell Podcast as part of IBN’s...

PXMD : 0.2401 (-1.52%)
Urgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in Malawi

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation...

PXMD : 0.2401 (-1.52%)
PaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has made a key announcement regarding the development of its proprietary PAX-101, an IV...

PXMD : 0.2401 (-1.52%)
PaxMedica (NASDAQ: PXMD) Responding to Emergency Request for IV Suramin from African Health Ministry

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has received an urgent request from the Ministry of Health (“MOH”) of Malawi requesting...

PXMD : 0.2401 (-1.52%)
PaxMedica (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has completed the execution of three pivotal registration/validation batches of PAX-101,...

PXMD : 0.2401 (-1.52%)
PaxMedica (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Conditions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”)...

PXMD : 0.2401 (-1.52%)
PaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more...

PXMD : 0.2401 (-1.52%)
PaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder...

PXMD : 0.2401 (-1.52%)
PaxMedica (NASDAQ: PXMD) Shares Innovations in ASD Treatments in Updated Presentation

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview...

PXMD : 0.2401 (-1.52%)

Barchart Exclusives

NVDA Earnings, Fed Speakers and Other Key Things to Watch This Week
There was some wild volatility last week as PPI came in hotter than expected and CPI came in just under expectations on the monthly basis. This small decrease in the inflation rate was enough for Fed heads to start talking about rate cuts again the next day. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar